CMP PHARMA, INC. – Trademark Portfolio

Entity Type: 03

CMP PHARMA, INC. holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 10 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 7 trademarks are registered. Notable registered marks include SPS, ORACIT, TRIANEX, CAROSPIR, and ABSORBASE. The owner is based in FARMVILLE, NC.

POST OFFICE BOX 147

FARMVILLE, NC 27828

11 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

CMP PHARMA, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (10 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

3
Cosmetics & Cleaning (1 filing)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

Frequently Asked Questions

How many trademarks does CMP PHARMA, INC. have?

CMP PHARMA, INC. has 11 U.S. trademarks filed with the USPTO. Of these, 7 registered, 4 cancelled.

What trademark classes does CMP PHARMA, INC. file in?

CMP PHARMA, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are CMP PHARMA, INC.'s most well-known trademarks?

CMP PHARMA, INC.'s registered trademark portfolio includes well-known marks such as SPS, ORACIT, TRIANEX, CAROSPIR, and ABSORBASE. These are among 7 currently registered trademarks in the portfolio.

What is CMP PHARMA, INC.'s trademark registration success rate?

CMP PHARMA, INC. has a 64% trademark registration rate, with 7 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.